Mice receiving statolon intraperitoneally were 1,000 times more resistant to intraperitoneal challenge with mengovirus than were untreated controls. Protection was afforded when statolon was administered 1 day before or 1 day after intraperitoneal inoculation with the virus. No therapeutic effect was observed when treatment with statolon was delayed for 2 days or more after virus infection. Exposure of mice to a simulated space cabin environment did not increase their susceptibility to the lethal effects of mengovirus infection or eliminate the protective effect of statolon.
Statolon is a complex derivative obtained from cultures of Penicillium stoloniferum (7) . Among its most outstanding properties are relative nontoxicity to an intact host and ability to induce interferon release both in vivo and in vitro (6) . These characteristics suggest that statolon might be not only a useful tool in studies on the interaction of host cells and viruses but possibly also of value in prevention of certain viral diseases. We selected this compound for a study of its activity against the lethal effect of mengovirus in mice. Its protective effect in animals maintained under normal conditions was compared with that observed in mice exposed to a simulated space cabin environment.
MATERIALS AND METHODS
Animals. Male Swiss albino mice (22 to 26 g) were quarantined for 2 weeks in an air-conditioned facility at 20 C after their arrival from a commercial source.
No deaths or illness was observed during this peiiod. They were then randomly divided into two groups. One group was retained in the animal room while the other was transferred to a biosimulator for a 2-week period of acclimatization. This instrument and its supporting equipment have been described previously (3) Virus. The large plaque-forming variant of mengovirus, propagated in monolayers of L cells and appropriately diluted in PBS, was inoculated intraperitoneally in 0.2-mi amounts. Groups of normal mice and those treated with statolon 24 hr previously received virus dilutions ranging from l0-4 to 10-7. All those mice which were given statolon on the same day or on any day after the virus inoculation received the 10-5 virus dilution. The mice were observed daily for illness or death.
RESULTS
Among the nonprotected controls (no statolon), the earliest deaths occurred on the 5th day after inoculation and were limited to animals receiving the highest concentrations of virus. The greatest number of deaths was recorded between the 6th and 8th days. Animals surviving 10 days postinoculation without visible signs of illness were considered to be refractory to the infectious challenge. The experiment was terminated on the 10th day.
The LD5o (10 days) dose was determined from data presented in Table 1 , by use of probit analysis. Results with this method were in essential agreement with those obtained by use of the Reed and Muench or Dragstedt and Behrens methods. Statistical analysis has shown that, among the nonprotected animals, there was no significant difference between the resistance of mice at ground-level conditions and those kept in the biosimulator. The respective LD5o doses were 10-5.30 and 105 6l
When comparable groups of mice were given 250 ug of statolon 24 hr before inoculation with the virus, only 2 mice died in the biosimulator (on the 7th and 8th days) and 1 mouse died under the ground-level conditions (on the 10th day). In each instance, the mice were in the groups inoculated with the 10-i dilution of virus. It can be seen from the results given in Table 1 that, in the biosimulator, pretreatment with statolon (24 hr) leads to an increase in the LD50 dose value to 10-22. Because of the dilution range employed, it was not possible to estimate the LD50 for the group kept at ground-level conditions. However, it appears that the administration of statolon increased the LD5o by a factor of 1,000 or more. Table 2 summarizes the results obtained when the treatment with statolon was delayed up to 3 days after virus inoculation. The level of protection conferred by treatment with statolon only 5 min preceding the virus inoculation was essentially the same as that achieved when the statolon was administered 24 hr before the virus was injected. Significant protection was also seen among the mice kept at ground-level conditions which received statolon 1 day after the challenge with the virus. The mortality rate of mice treated at 2 and 3 days after virus challenge did not differ significantly from that found for untreated animals.
DISCUSSION
The work of Powell and co-workers (11) , dealing with chemoprophylactic properties of a filtrate from a Penicillium culture against MM and Semliki Forest viruses, stimulated further search for compounds which could elicit protection against viruses similar to that offered by antibiotics in bacterial infections. These investigations dealt with crude filtrates of mold cultures and led to a more purified and concentrated preparation called "statolon." This preparation was described as a complex anionic polysaccharide derived from P. stoloniferum (7) . When injected intraperitoneally or intravenously, it induces the release of a viral inhibitor with biological properties consistent with those of interferon (5) . In mice, a maximal interferon level is attained at 12 hr, and the level remains relatively high for an additional 12 hr. By 72 hr, however, the interferon level has decreased to a lower plateau which is maintained for at least another 4 days. The protective effect of a single injection of statolon against MM virus may persist for 30 days or longer (W. J. Klienschmidt and E. B. Murphy, Bacteriol. Rev., in press).
The production of interferons in many in vitro and in vivo systems may be induced by such diverse agents as viruses (13), bacterial endotoxins (15), mold filtrates, and phytohemagglutinin (14) . Interferons are known to render the cells incapable of reproducing a wide spectrum of viruses without having a direct effect on the virus particles themselves. However, aside from the demonstrated species specificity (9), certain differences among interferons are known to exist, i.e., their mode of release (15) , molecular weight (8), heat (4, 14) , and pH stability (8, 14) . These differences warrant rather detailed investigations of the particular interferons in regard to their viral spectrum as well as the time elapsing between the introduction of the viral agent and the substance affecting the release of the interferon. Since statolon appears to be nontoxic at the effective dosages and may be introduced subcutaneously (2), it seems to offer certain advantages over other compounds capable of eliciting a similar effect.
In addition to other viruses already reported (1, 2, 6, 10, 12) , our results show that statolon is 
